Treatment of Internal Carotid Artery Aneurysms with a Covered Stent: Experience in 24 Patients with Mid-Term Follow-up Results

Isil Saatci, H. Saruhan Cekirge, M. Halil Ozturk, Anil Arat, Fikret Ergungor, Zeki Sekerci, Engin Senveli, Uygur Er, Sami Turkoglu, Osman E. Ozcan and Tuncalp Ozgen

http://www.ajnr.org/content/25/10/1742
Treatment of Internal Carotid Artery Aneurysms with a Covered Stent: Experience in 24 Patients with Mid-Term Follow-up Results

Isil Saatci, H. Saruhan Cekirge, M. Halil Ozturk, Anil Arat, Fikret Ergungor, Zeki Sekerci, Engin Senveli, Uygur Er, Sami Turkoglu, Osman E. Ozcan, and Tuncalp Ozgen

BACKGROUND AND PURPOSE: We present our preliminary experience, including mid-term angiographic and clinical follow-up results, with an alternative technique for the endovascular treatment of intracranial aneurysms in a series of patients. This new method, previously described in anecdotal case reports, consists of endovascular deployment of an artificial vessel graft (stent graft or covered stent) in the parent vessel to exclude the intracranial aneurysm sac from circulation.

METHODS: Twenty-five internal carotid artery (ICA) aneurysms in 24 patients were successfully treated by using a Jostent coronary stent graft deployed in the parent artery across the aneurysm neck. All except four aneurysms were extradural, located in the petrous or cavernous portion of the ICA. The four intradural aneurysms were located in the carotico-ophthalmic region. Seventeen aneurysms in 16 patients occurred posttraumatically, secondary to motor vehicle accidents or surgical injury.

RESULTS: Twenty-three aneurysms were immediately excluded from circulation after stent graft placement. In two aneurysms, a slow contrast material filling (endoleak) into the aneurysm cavity was observed immediately after treatment. One was thrombosed, as shown by late control angiography; in the other one, a second larger bare stent was used to appose the stent graft’s distal end to the ICA wall, thus sealing the endoleak into the distal graft. No technical adverse event, including vessel dissection, vessel perforation, or thromboembolism, occurred with or without clinical consequence. No mortality or morbidity developed during or after the procedure, including the follow-up period. Two-year control angiography in one patient, 1.5-year control angiography in two patients, 1-year control angiography in six patients, and 6-month control angiography in 12 patients were performed, revealing reconstruction of the ICA with no aneurysm recanalization. All symptoms resolved after treatment in the patients who had initially presented with mass effect.

CONCLUSION: Initial anatomic, clinical and mid-term follow-up results in this small series of patients are encouraging. This technique has been proved to have potential in the reconstructive treatment of intracranial aneurysms. Further research and development are needed to optimize the stent graft technology for the cerebrovascular system.

Endovascular treatment of cerebral aneurysms with detachable coils has now been proven to be a superior alternative to open microsurgery in terms of survival free of disability at 1 year, according to the recently published large randomized International Subarachnoid Aneurysm Trial (ISAT), which studied patients with ruptured aneurysms (1). Despite this, recanalization of the aneurysms with recurrences in 10–20% of patients after coil placement is still the main drawback of the endovascular technique. The recanalization rate is even higher in complicated, wide necked, large, or giant aneurysms treated with detachable coils (2). Such aneurysms also represent serious difficulties for the surgeon—in particular, aneurysms that are large or giant sized and located in the internal carotid artery (ICA)—because of bony obstacles and difficulty in proximal control (3, 4). Because of
these drawbacks, interventional neuroradiologists and medical technology have been urged to create more innovative techniques for better endovascular reconstructive treatment options (5, 6). One of these recent advances is the use of stents deployed across the aneurysm neck in the parent artery for the reconstructive endovascular treatment of challenging aneurysms in combination with intra-aneurysmal filler materials, such as metallic coils or liquid polymer Onyx (6–8), leading to favorable outcomes. We present an advanced reconstruction technique with which a stent graft is deployed in the parent artery to exclude the cerebral aneurysms from circulation. Although the use of stent grafts in the endovascular aneurysm treatment has been previously described as anecdotal experiences in various case reports, this article, for the first time in the English literature, presents data from a series of patients in whom this technique has been used, including midterm angiographic and clinical follow-up.

### Patients and Techniques

This study included 25 ICA aneurysms in 24 patients, successfully treated at a single institution by using the Jostent coronary stent graft (Jomed international, Helsingborg, Sweden) placed in the parent artery across the aneurysm neck during the period from December 2001 through December 2003. During that time, 418 intracranial aneurysms were treated by endovascular methods. These 24 patients represented all the patients whose aneurysms were treated with this technique (i.e., no technical failures had occurred, as this group consisted of highly selected cases, especially in terms of proximal vascular tortuosity). Patient age ranged from 17 to 59 years; 16 were male and eight were female patients. All except four aneurysms were extradural, being located in the petrous and/or cavernous portion of the ICA. The remaining four aneurysms were located in the carotico-opthalmic portion of the ICA. In one patient, two posttraumatic ICA aneurysms in the same carotid artery were excluded from circulation with a single graft. Seventeen aneurysms (in 16 patients) were post-traumatic, secondary to motor vehicle accidents (13 patients) or surgical injury (three patients). Six of the 16 patients had severe nasal bleeding at presentation. Several patients had mass effect symptoms (e.g., severe headache in five and varied cranial nerve palsies in nine patients). Two patients were treated after subarachnoid hemorrhage, and both recovered well without any neurologic deficit. Detailed clinical information is provided in Table 1.

This treatment was considered for the aneurysm group in which mass effect was the principal symptom; for very wide or fusiform neck aneurysms for which conventional modalities were likely to result in recanalization, except for the stent and Onyx combination, which is more complicated than single stent deployment; and for bizarrely shaped or dissecting aneurysms.

### Patient demographics, aneurysm location and size, clinical data, post-procedural clinical and angiographic follow-up

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Aneurysm Location</th>
<th>Size (mm)</th>
<th>Mass Effect</th>
<th>Trauma</th>
<th>Control Angiography</th>
<th>Mass Effect Early Outcome*</th>
<th>Mass Effect Late Outcome*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>55</td>
<td>M</td>
<td>R. cav</td>
<td>33 x 28</td>
<td>6n Palsy</td>
<td>+</td>
<td>6 month</td>
<td>Full recovery</td>
<td>Stable</td>
</tr>
<tr>
<td>2</td>
<td>22</td>
<td>M</td>
<td>R. cav</td>
<td>34 x 29</td>
<td>Headache</td>
<td>+</td>
<td>1 year</td>
<td>Improved</td>
<td>Full recovery</td>
</tr>
<tr>
<td>3</td>
<td>48</td>
<td>F</td>
<td>R. petrocav</td>
<td>27 x 31</td>
<td>Headache</td>
<td>+</td>
<td>NA</td>
<td>Improved</td>
<td>NA</td>
</tr>
<tr>
<td>4</td>
<td>49</td>
<td>M</td>
<td>L. cav</td>
<td>15 x 20</td>
<td>6n and 3n Palsy</td>
<td>-</td>
<td>NA</td>
<td>Full recovery</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>18</td>
<td>M</td>
<td>L. cav</td>
<td>16 x 24</td>
<td>None</td>
<td>+</td>
<td>6 month</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>6</td>
<td>23</td>
<td>M</td>
<td>L. cav</td>
<td>39 x 33</td>
<td>2n Palsy</td>
<td>+ (β)</td>
<td>2 year</td>
<td>Full recovery</td>
<td>Stable</td>
</tr>
<tr>
<td>7</td>
<td>54</td>
<td>M</td>
<td>R. cav</td>
<td>20 x 17</td>
<td>Headache</td>
<td>-</td>
<td>6 month</td>
<td>Improved</td>
<td>Full recovery</td>
</tr>
<tr>
<td>8</td>
<td>43</td>
<td>F</td>
<td>R. cav</td>
<td>22 x 15</td>
<td>6n Palsy</td>
<td>+</td>
<td>6 month</td>
<td>No change</td>
<td>Full recovery 6 months</td>
</tr>
<tr>
<td>9</td>
<td>32</td>
<td>M</td>
<td>L. cav</td>
<td>14 x 21</td>
<td>None</td>
<td>+ (β)</td>
<td>6 month</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>10</td>
<td>25</td>
<td>M</td>
<td>L. petrocav</td>
<td>5 x 7</td>
<td>None</td>
<td>+ (β)</td>
<td>1 year</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>11</td>
<td>35</td>
<td>M</td>
<td>R. cav</td>
<td>21 x 17</td>
<td>Headache</td>
<td>+</td>
<td>1 year</td>
<td>Improved</td>
<td>Full recovery</td>
</tr>
<tr>
<td>12</td>
<td>34</td>
<td>M</td>
<td>R. caroticooph</td>
<td>37 x 25</td>
<td>Total ophthalmoplegia</td>
<td>+</td>
<td>18 month</td>
<td>Full recovery</td>
<td>Stable</td>
</tr>
<tr>
<td>13</td>
<td>59</td>
<td>F</td>
<td>L. caroticooph</td>
<td>14 x 17</td>
<td>None (SAH)</td>
<td></td>
<td>6 month</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>14</td>
<td>43</td>
<td>M</td>
<td>L. cav</td>
<td>27 x 20</td>
<td>Total ophthalmoplegia</td>
<td>+</td>
<td>18 month</td>
<td>Partial recovery</td>
<td>Full recovery 6 months</td>
</tr>
<tr>
<td>15</td>
<td>18</td>
<td>M</td>
<td>L. petrocav</td>
<td>12 x 14</td>
<td>None</td>
<td>+ (β)</td>
<td>6 month</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>16</td>
<td>22</td>
<td>M</td>
<td>R. petrocav</td>
<td>9 x 6</td>
<td>None</td>
<td>+ (β)</td>
<td>6 month</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>17</td>
<td>34</td>
<td>M</td>
<td>L. cav</td>
<td>28 x 34</td>
<td>3n Palsy</td>
<td>-</td>
<td>1 year</td>
<td>Partial recovery</td>
<td>Full recovery 6 months</td>
</tr>
<tr>
<td>18</td>
<td>17</td>
<td>F</td>
<td>L. cav</td>
<td>18 x 14</td>
<td>6n Palsy</td>
<td>+</td>
<td>1 year</td>
<td>Full recovery</td>
<td>Stable</td>
</tr>
<tr>
<td>19</td>
<td>23</td>
<td>M</td>
<td>L. cav</td>
<td>16 x 11</td>
<td>None</td>
<td>-</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>20</td>
<td>27</td>
<td>F</td>
<td>L. caroticooph</td>
<td>9 x 7</td>
<td>None</td>
<td>-</td>
<td>6 month</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>21</td>
<td>29</td>
<td>M</td>
<td>L. cav</td>
<td>4 x 3</td>
<td>None</td>
<td>+ (β)</td>
<td>6 month</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>22</td>
<td>36</td>
<td>F</td>
<td>L. petrous</td>
<td>24 x 28</td>
<td>Headache</td>
<td>+</td>
<td>6 month</td>
<td>Full recovery</td>
<td>Stable</td>
</tr>
<tr>
<td>23</td>
<td>24</td>
<td>F</td>
<td>R. caroticooph</td>
<td>3 x 4</td>
<td>None (SAH)</td>
<td>-</td>
<td>1 year</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>24</td>
<td>34</td>
<td>F</td>
<td>R. cavernous</td>
<td>22 x 27</td>
<td>3n Palsy</td>
<td>+</td>
<td>6 month</td>
<td>Partial recovery</td>
<td>Full recovery</td>
</tr>
</tbody>
</table>

Note.—α indicates patients in whom ophthalmic artery was covered with the stent graft; M, male; F, female; R, right; L, left; cav, cavernous internal carotid artery; petrocav, petrous and cavernous portion of the internal carotid artery; caroticooph, carotico-opthalmic segment of the internal carotid artery; 6n, sixth nerve; 3n, third nerve; 2n, second nerve; SAH, subarachnoid hemorrhage; β patients who had nasal bleeding; NA, not applicable because the time interval since treatment was >6 months and no control angiography had yet been performed.

* Control Angiography, latest angiography performed; Mass Effect Early Outcome, evaluation of mass effect symptom at end of second week; Mass Effect Late Outcome, evaluation during clinical follow-up (during third month unless otherwise indicated).

Aneurysms were partially thrombosed.
in which endosaccular occlusion is not seemingly feasible. In this subset of aneurysms, two additional criteria were taken into consideration before attempting this treatment option: 1) the relevant carotid artery should not be tortuous with deep curves (e.g., for the ophthalmic aneurysms, the cavernous segment of the ICA should be C-shaped rather than U-shaped); and 2) the aneurysms should be definitely proximal to the origin of the anterior choroidal artery. The posterior communicating artery origin can be covered with the stent in selected cases, if necessary, in cases in which the posterior communicating artery is not of fetal type with a patent ipsilateral P1. Except for patient 20, in whom the seal test for Onyx failed, no other previous treatment had been attempted in any of the patients.

After placement of a 6-French Envoy guiding catheter (Cordis-Johnson & Johnson, Miami Lakes, FL) in the ICA, the aneurysm was bypassed with a microcatheter distal to the aneurysm neck. A 300-cm 0.014-in Choice extra support coronary exchange wire (Scimed, Boston Scientific, Maple Grove, MN) was placed through the microcatheter. A Jomed coronary stent graft, the size of which was determined before the procedure, was then navigated over the exchange wire and placed across the aneurysm neck. Multiple control angiograms were obtained to confirm full coverage of the aneurysm neck by the graft. The balloon-expandable stent graft was then deployed across the aneurysm neck. The balloon of the stent graft was always inflated very slowly up to the nominal pressure of 12 atm. If the size of the ICA was bigger than 4 mm, the balloon was slowly inflated up to 16 atm, at which the stent graft diameter increased to 4.4 mm, especially in the petrous portion of the ICA.

Eighty-centimeter 7-French reinforced long Arrow introducer sheaths (Arrow International, Inc., Reading, PA) were used for all patients, regardless of the aortic arch tortuosity, to ensure enough support for the 6-French guiding catheter. In some instances, Arrow sheaths were placed even in the ICA to avoid “kickbacking” of the guiding catheter when advancing further into the petrous ICA and to obtain the necessary push force for the stent graft to the desired location (Fig 1). When distal positioning of the Arrow sheath and guiding catheter for further support was necessary, they were advanced over the shaft of the stent graft and the extra support wire after the stent graft reached into the proximal cavernous portion. During navigation of the stent graft, vasospasm of the vessel, caused by a rigid coronary exchange wire, long reinforced sheath or stent graft, was treated by intra-arterial injections of 100 to 200 μg of nitroglycerine, repeated when necessary. Before deployment of the graft, extreme care was taken by viewing multiple angiograms to confirm positioning and to not cover any important side branch, such as the anterior choroidal artery, especially in the intradural segment of the ICA (Fig 1). The ophthalmic artery origin was covered with the graft, if necessary (Fig 2).

After deployment of the stent graft, control angiographies were obtained, confirming the exclusion of the aneurysm sac from the circulation. If contrast material endoleak was present in the aneurysm sac, the balloon of the deployed stent was re-inflated in the proximal and distal ends of the graft to better appose it to the vessel wall for the full exclusion of the aneurysm from circulation.

All the procedures were performed with the patients under general anesthesia, with IV administered heparinization maintaining the activated clotting time at 2.5 times the basal level. Our management protocol after intracranial stent placement included immediate post-treatment cranial CT, which was performed in all cases to exclude any intracranial hemorrhage due to stiff coronary exchange wire. Clopidogrel (300 mg) was then administered to the patients through the nasogastric tube, immediately after CT confirmed normal findings. In addition to clopidogrel, the IV administered heparinization was continued for 24 hours. The patients were discharged with daily doses of 75 mg of clopidogrel, 300 mg of aspirin, and 2 × 0.6 mg of low molecular weight heparin. The heparin was discontinued after 1 week, but the patients were to continue receiving 75 mg of clopidogrel and 300 mg of aspirin per day until control angiography was performed at 1 year. After the 1-year control angiography was performed, the patients were to receive only 300 mg of aspirin daily.

Detailed neurologic examinations were performed before treatment, immediately after treatment, 2 weeks after treatment, and later during follow-up. The patient who had second nerve palsy at presentation (patient 6) underwent ophthalmologic examinations during the pre- and post-treatment evaluations. CT and MR imaging were performed for all patients.

Results

Twenty-five intracranial aneurysms were treated by using the Jomed covered stent graft. In eight patients, transient endoleaks into the aneurysm sac were observed immediately after the deployment and were easily avoided by balloon re-inflation in the proximal and distal ends of the graft to appose it to the vessel wall for the full exclusion of the aneurysm from the circulation in six aneurysms. In two aneurysms, a slow contrast material endoleak into the aneurysm persisted despite balloon re-inflation. In one of the two, a second larger (4.5 mm) bare stent (Boa stent, Balt Montmorency, France) was used to appose the distal end of the stent graft to the ICA wall, which was larger than the maximum diameter of the stent graft,
sealing the endoleak into the distal graft. The remain-
ning aneurysm with initial endoleak after stent deploy-
ment was shown by late control angiography to have 
complete thrombosis (Fig 3) despite absence of fur-
ther intervention.

No morbidity or mortality occurred in any of the 
patients during or after the treatment, including the 
follow-up period. No technical adverse event, includ-
ing vessel perforation or thromboembolism, occurred. 
Despite very distal positioning of the guiding catheter 
and the Arrow sheath in several patients, vessel dis-
section did not occur in any of the patients, possibly 
because these were navigated over the shaft of the 
stent graft, which had already been placed in the 
proximal cavernous ICA over the extra support wire.

Post-treatment CT confirmed the uneventful proce-
dure, with no evidence of bleeding. None of the post-
treatment MR images revealed any significant ischemic 
lesions, except for a few tiny foci of diffusion abnormal-
ity, not necessarily in the relevant vascular territory.

Control angiography performed at 2 years in one 
patient (Fig 3), at 1.5 years in two (Fig 2), at 1 year in 
six, and at 6 months in 12 confirmed complete recon-
struction of the ICA, with no recurrent aneurysmal 
filling. No hemodynamically significant stenosis of the 
ICA was revealed by the control angiography. In one 
patient, some intimal hyperplasia that did not cause 
significant stenosis was noted at the proximal edge of 
the stent graft (Fig 4).

Cranial nerve palsies (nine patients) showed com-

Fig 2.
A. Giant right carotico-ophthalmic aneurysm.
B. Oblique image of stent graft placed across the aneurysm neck before its deployment. Note that the ophthalmic artery is covered 
with the graft but not the anterior choroidal artery.
C. Non-subtracted view of the deployed stent graft (curved arrow). Note the contrast material trapped in the aneurysm sac because 
of the immediate exclusion.
D. Oblique angiogram obtained after treatment reveals the reconstruction of the ICA. Note that the ophthalmic artery is not filling but 
the anterior choroidal artery origin is preserved.
E. Oblique control angiogram obtained 18 months later shows no stenosis.
Complete resolution in five patients, partial resolution in three patients, and no change in one patient during the 2-week postoperative period. In the four patients with partial resolution and no change of cranial nerve palsies, the symptoms were shown to be fully resolved by the 3- or 6-month clinical control angiography. In eight patients in whom the ophthalmic artery origin was covered with the stent graft, no clinical problem occurred because of the reconstruction of the ophthalmic artery via external carotid artery collaterals (Fig 5). All patients, including those who had no pain at presentation, suffered from headache during the early post-treatment days, presumably because of fast thrombosis of the aneurysm sac. However, all patients were subsequently relieved of headache (detailed post-treatment data are presented in Table 1).

Discussion

Varying endovascular treatment alternatives currently are available for the management of cerebral aneurysms. 3D coil technology and balloon remodeling techniques have been very important advances (5, 9). During recent years, new treatment materials and
techniques offering a different concept in endovascular reconstruction have been described for the more complicated broad necked, fusiform, and large and giant aneurysms. One of these is the use of liquid embolic Onyx (MTI-tv3 Inc., Irvine, CA) for cerebral aneurysm treatment, both with or without stent, which has recently been reported in the literature (6, 10). These studies have shown that Onyx can produce durable aneurysm occlusion in patients with difficult large and giant wide necked intracranial aneurysms in whom other endovascular techniques are likely to fail and for whom surgery carries substantial morbidity risk. The clinical results and complication rates seem comparable to those of other endovascular techniques for similar patient populations, but the final complete occlusion rate of 79% seems significantly better than those reported for this type of aneurysm with coil treatment (10). To obtain more stable aneurysm occlusion, the combination of stents and detachable coils has been suggested for both extradural and intradural aneurysms (7, 8, 11, 12). However, a considerable rate of incomplete occlusion is associated with the stent and coil combination, resulting in recanalization of 20% in the follow-up studies after treatment of complicated aneurysms (8). In the above noted studies, the combination of stents with either Onyx or coils was suggested as an alternative treatment to balloon remodeling or parent vessel occlusion (6–8, 11, 12). However, the clinical use of stent for aneurysm treatment has certain limitations because of difficult navigation of stents within the cerebral vasculature. Improvements in technology providing better navigation of the stents have enabled us to use them more frequently in our routine practice, transforming this technique into a very effective endovascular therapeutic alternative for the treatment of wide necked or complicated aneurysms (giant, fusiform, pseudoaneurysms).

The use of artificial endoluminal vessel grafts (stent grafts) has emerged as a very effective therapeutic alternative to surgical reconstruction techniques during the last decade, and their use in the treatment of aortic and peripheric aneurysms, acute coronary and peripheric artery ruptures, and peripheric AVF (13–17) has already been reported in the literature. A few reported cases describe stent graft use in the head and neck arteries (18–20). Anecdotal cases have shown that stent graft treatment would be very effective for the endovascular management of skull base aneurysms and fistulae, carotid blow-out syndrome in the neck, and iatrogenic injury of the cavernous ICA leading to massive epistaxis and caroticocavernous fistula (21, 22). Chiaradio et al (23) reported the use of stent graft for the treatment of a ruptured fusiform dissecting aneurysm of the intracranial vertebral artery. Islak et al (24) reported two cases in which they successfully excluded a giant fusiform vertebrobasilar junction and an ophthalmic aneurysm from the circulation by using a stent graft. They achieved stable short-term follow-up results. It is very clear that closure of the side branches coming from the treated segment of the artery where the graft is deployed is the main concern in the use of a covered stent for cerebral aneurysm treatment. This report limited the use of the device to certain anatomic locations from which perforating or side branches originate, such as the posterior communicating or anterior choroidal artery.

The Jomed coronary stent graft originally had a sandwich-like design to fix a thin polytetrafluoroethylene (PTFE) membrane between two stainless steel stents. Later, the stent graft design was refined to
extend the membrane up to the stent edges because restenosis was noticed to be developing at the proximal and distal ends, which were not covered with the membrane (25). PTFE membrane is the best available covering material for the stent grafts in terms of patency rates. Restenosis rates between 24% and 38% have been reported in studies using Jomed coronary stent grafts in cases of coronary atherosclerosis, which is not different from the restenosis rates of regular bare stent placement. Although the design of the stent graft was refined, restenosis still occurred, primarily at the stent edges rather than within the stent (26–28). In eight reported cases, the Jomed coronary stent graft was used to exclude nonatherosclerotic coronary artery aneurysms from circulation. Follow-up angiography performed up to 18 months later showed excellent results, with no restenosis (27, 29, 30). Moreover, very favorable results with low rates of neointimal hyperplasia indicating the antiproliferative effect of sealing the vessel wall have been shown in the reports documenting the vascular wall response in not only the coronary but also peripheral arteries with the use of PTFE-covered stents (21). Laboratory investigations on PTFE-covered stents also supported these clinical experiences, whereas Dacron- and silicone-covered stents have poor patency rates secondary to acute inflammation and extreme fibrous connective tissue ingrowth (21).

Encouraged by these favorable results in the literature, we decided to use stent grafts for the endovascular treatment of cerebral aneurysms. Twenty-five ICA aneurysms located on the petrous, cavernous, and ophthalmic segments were successfully excluded from the circulation with the placement of grafts. The treatment resulted in occlusion of the ophthalmic artery in eight patients. This was accepted before the treatment, and reconstruction of the ophthalmic artery from the extracarotid artery collaterals was seen in all patients, as anticipated (Fig 5). Balloon occlusions of the ICA, for the treatment of ICA aneurysms with the intentional occlusion of the ophthalmic artery to avoid the retrograde flow into the aneurysm sac, have been performed during the last 2 decades, resulting in no ocular symptoms. However, extreme caution has been undertaken not to cover the anterior choroidal artery origin during graft placement across the neck of the ophthalmic aneurysms (Fig 1).

This technique has associated difficulties and risks because we do not have stent grafts especially designed for use in cerebral vasculature; we use coronary stent grafts. The limited flexibility is the main technical limitation; it is difficult to adapt a rigid stent designed for coronary use to the curves of the neurovascular anatomy associated with the poor navigation of the stent graft in the cerebral arteries. Possible complications that may result from this rigidity are dissection and vasospasm of the cerebral arteries. However, if necessary precautions are taken both in case selection and during the procedure by using intra-arterial nitroglycerine injections and necessary interventional adjunctive tools as described, technical success can be achieved with no harm to the patient (21). Nevertheless, we emphasize that the presence of significant vessel tortuosity hindered us from attempting this treatment technique in some cases at the case selection stage.

Stent patency rates have not been of great concern in the treatment of complicated cerebral aneurysms because the stents are placed in the nonatherosclerotic vessels. No hemodynamically significant vessel stenosis was reported in the series that combined stents with detachable coils or liquid embolic Onyx for cerebral aneurysm treatment (6, 8, 10). However, treating aneurysms with covered stents is considered to be more logical without deployment of any embolizing materials in the aneurysm sac, which may complicate the procedure and enhance the risk associated with the treatment. We think that this technique offers not only a solution to the issue of mass effect of the aneurysms but also a much more definitive reconstructive treatment than that provided by endosaccular aneurysm treatment combined with stents, which continues to have associated recanalization problems (8). Moreover, this technique is a very valuable treatment alternative for dissecting aneurysms for which neither endosaccular embolization nor surgical reconstruction is possible (Fig 1).

The follow-up data in our series are very encouraging. No hemodynamically significant stenosis was shown by the late control angiography, performed up to 2 years later, similar to the combined stent and coil/Onyx treatment series (6, 8). Although the long-term patency rate of stent grafts in the cerebral aneurysms is still unknown, with this experience, we expect a positive long-term outcome in terms of parent artery patency because the intimal hyperplasia, a consequence of the foreign body reaction in the vascular wall, usually occurs within the first few months of the treatment and usually becomes stable with time. However, we need to confirm this with long-term follow-up angiography in this series.

Our report, to our knowledge, is the first to show the use of stent grafts in the cerebral aneurysm treatment in a series of patients with mid-term follow-up results. The exclusion of cerebral aneurysms from circulation with the use of stent grafts placed across the aneurysm neck proved to be effective. However, an appropriate case selection is crucial for successful results. This technique would be a very effective alternative treatment for the intracranial aneurysms located at the ICA below the level of the anterior choroidal and posterior communicating artery or for any location that is free of side wall branches or perforating arteries. This treatment warrants more research and development to create better stent graft designs dedicated to neurovascular use to solve the present limitations.

References


